Hi @Wilba32 ! Thought I'd jump on this sleuthing run..
Looking through the clinicaltrials.gov site searching 'COVID-19' and 'NIH', it spat out 71 replies.
Parsing through the search, I was looking for any NIH involvement, whether as a sponsor or study-support, and it yielded some interesting results.
1. The HCQ study in the Philippines was withdrawn (effective 9 Nov)
2. There's a B and T-cell repertoire and immune response study (not a treatment, just an investigation)
3. There's a P2 RCT trial looking at Fostamatinib (an SYK inhibitor - basically it inhibits pro-inflammatory cytokines by monocytes and macrophages (similar to Rem-L's MOA in one facet, but I fail to see how its gonna address the need for anti-inflammatory cytokines that plays a role in stimulating regeneration in inflamed tissue - this is the big reason why we were seeing more light being shed on the 'long covid' patients, and why Rem-L, in our generation, needs to be approved precisely for the complete eradication of C-19 in even the recovered patients.), decreased production of neutrophil extracellular traps (NETs) by neutrophils, and inhibition of platelet aggregation; three pathways that are mediated through Fc receptors (FcR) recognition of antigen-antibody complexes or activation of c-type lectin receptors (CLEC)So to answer you, Rem-L's the only NIH one that's the most promising right now.
- Forums
- ASX - By Stock
- MSB
- Ann: DSMB Analysis Recommends to Continue P3 COVID-19 ARDS Trial
Ann: DSMB Analysis Recommends to Continue P3 COVID-19 ARDS Trial, page-285
-
-
- There are more pages in this discussion • 108 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.03 |
Change
0.080(8.42%) |
Mkt cap ! $1.176B |
Open | High | Low | Value | Volume |
95.5¢ | $1.03 | 95.0¢ | $43.38M | 42.28M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 72752 | $1.01 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.03 | 205100 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 20000 | 1.005 |
5 | 57985 | 1.000 |
1 | 50000 | 0.995 |
2 | 20525 | 0.990 |
1 | 10000 | 0.985 |
Price($) | Vol. | No. |
---|---|---|
1.035 | 190122 | 7 |
1.045 | 39714 | 5 |
1.050 | 21696 | 6 |
1.060 | 9750 | 2 |
1.065 | 5780 | 1 |
Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, MD & CEO
Anthony Noble
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online